NPS Pharmaceuticals to Report Third Quarter 2012 Financial Results

  NPS Pharmaceuticals to Report Third Quarter 2012 Financial Results

Business Wire

BEDMINSTER, N.J. -- November 06, 2012

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will issue
its third quarter 2012 financial release on Friday, November 9, 2012 at
approximately 8:00 a.m. ET. The press release will be followed by a conference
call and webcast at 8:30 a.m. ET.

To participate in the conference call, dial (800) 299-9086 and use passcode
55167232. International callers may dial (617) 786-2903, using the same
passcode. In addition, a live audio of the conference call will be available
over the Internet. Interested parties can access the event through the
investors’ calendar of events page on the NPS website,

If you are unable to participate in the live call, a replay will be available
at (888) 286-8010, with passcode 27933265 until midnight ET, November 23,
2012. International callers may access the replay by dialing (617) 801-6888,
using the same passcode. The webcast will also be available through the NPS
website for the same period.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan
products to patients with rare disorders and few, if any, therapeutic options.
NPS is advancing two late-stage registration programs. A New Drug Application
is undergoing FDA review for Gattex® (teduglutide) as a treatment for adults
with short bowel syndrome (SBS) and a Biologic License Application is being
prepared for Natpara® (rhPTH[1-84]) in adult hypoparathyroidism. NPS' earlier
stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with
potential application in rare disorders involving increased calcium receptor
activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH).
NPS complements its proprietary programs with a royalty-based portfolio of
products and product candidates that includes agreements with Amgen,
GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin, and Nycomed, a
Takeda company.


NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335
Press spacebar to pause and continue. Press esc to stop.